SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech failure, 2002
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who started this subject3/22/2002 11:51:24 AM
From: michael_f_murphy   of 130
 
NeuroSearch and Grupo Ferrer discontinue the development of NS2710 for the treatment of anxiety

In December 2000, NeuroSearch and the Spanish pharmaceutical company Grupo Ferrer signed a development and licensing agreement regarding the drug candidate NS2710, which was in Phase II clinical studies for the treatment of anxiety.

NS2710 has demonstrated a significant improvement of anxiety disorders in patients. Concurrently with these results, some patients showed skin rashes, which could be caused by the treatment with NS2710. To clarify this, Grupo Ferrer has completed a clinical safety study. The results of the recently completed, placebo-controlled study showed a significantly larger prevalence of skin rashes in the group treated with NS2710, confirming the findings seen in previous clinical studies. The skin rashes are described as reversible, mild to moderate, and are not the result of an allergic reaction.

After an overall evaluation, NeuroSearch and Grupo Ferrer have decided to discontinue the further development of NS2710.

NeuroSearch and Grupo Ferrer are now discussing an expansion of the existing agreement into a research and development collaboration comprising anxiolytics and drugs for other CNS diseases.

Asger Aamund
Chairman

Contact person: Jørgen Buus Lassen, President & CEO
Tel: +45 4460 8211
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News